Airway Inflammation News and Research

RSS

Antibiotics provide no benefit in preventing recurrent wheezing in infants hospitalized with RSV

Antibiotics provide no benefit in preventing future recurrent wheezing in babies hospitalized with respiratory syncytial virus (RSV), according to a new study led by Washington University School of Medicine in St. Louis. And there is some evidence that antibiotics may make wheezing worse.

27 Feb 2022

Bedfont Scientific Ltd receives FDA clearance for NObreath® FeNO monitor

UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation.

31 Jan 2022

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

This study showed inhalable Covid-19 mimetic particle carriers as potential, versatile, aerosolizable COVID-19 vaccine candidates if worked on with continued optimization and refinement.

28 Jan 2022

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

A new study looks at the molecular level inhibition of the protective CFTR gene by the SARS-CoV-2 spike protein.

25 Jan 2022

Study suggests myeloid cell dysregulation is a driver of COVID-19 severity

Researchers determine the driving factors for disease severity and death due to COVID-19.

17 Jan 2022

Role of leptin in immune modulation and pathophysiology of COVID-19

A recent review paper in the journal Frontiers in Physiology discusses the role of leptins in infection with SARS-CoV-2 that triggered the ongoing COVID-19 pandemic.

13 Jan 2022

Scientists unravel how LPS prevents or promotes development of allergic disease

Immunologists have long been baffled by LPS, the bacterial lipopolysaccharide that helps form the cell walls of Gram-negative bacteria.

5 Jan 2022

Measuring airway inflammation when diagnosing and treating asthma patients

In this interview, Carol Stonham, the head of a Locality Based FeNO referral service, talks to NewsMed about measuring airway inflammation when diagnosing and treating asthma patients.

From Bedfont® Scientific Ltd 21 Dec 2021

Potential therapeutic targets of hydrogen for treatment of the COVID-19

A recent article provided a review of a study led by academician Zhong Nanshan, in China, on COVID-19 treatment by inhalation of a mixed gas composed of hydrogen and oxygen.

12 Nov 2021

Identification of common genes in COVID-19 and COPD

Based on protein-protein interactions, the paper shows the presence of ten genes that overlap between the two illnesses, also shared by several other deadly and debilitating diseases.

2 Nov 2021

Fermented soy product suppresses airway inflammation in animal models of asthma

Bronchial asthma causes symptoms such as wheezing and cough due to chronic airway inflammation, but there is no fundamental treatment for it, leaving a desire for new prevention and treatment methods.

26 Oct 2021

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, has previously been identified as endogenous peptide antagonist andinverse agonistof CXCR4 and is a promising compound for the development of improved analogues for the therapy of CXCR4-associated diseases.

18 Oct 2021

Role of neutrophil-epithelial interactions in SARS-CoV-2 infection

Researchers discuss the relationship between airway neutrophils and SARS-CoV-2 infection to determine the impact that neutrophils have on COVID-19.

15 Aug 2021

Study connects hyperglycemia and prolonged cloth mask use to COVID-19-associated mucormycosis risk

A new study conducted in India identifies the role of high blood sugar levels in predisposing patients to mucormycosis infection.

1 Aug 2021

Clinical trial to test personalized treatment for severe asthma caused by a specific mutation

Under a $10 million grant, a randomized, placebo-controlled clinical trial led by Boston Children's Hospital will test a personalized treatment for a form of severe asthma to which Black and Latinx children and adults are especially vulnerable.

21 Jul 2021

Thiol-based mucolytics show potent allosteric inhibition of SARS-CoV-2-ACE2 binding via disulfide reduction

A compelling report, recently released on the bioRxiv* preprint server, describes unexpectedly powerful inhibition of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by thiol-based mucolytic compounds P2119 and P2165, by preventing the virus spike from binding to its host cell receptor, the angiotensin-converting enzyme 2 (ACE2).

5 Jul 2021

Inhibiting necroptosis could be a novel approach for treating COPD

Research shows that inhibiting necroptosis, a form of cell death, could be a novel therapeutic approach for treating chronic obstructive pulmonary disease, an inflammatory lung condition, also known as emphysema, that makes it difficult to breathe.

17 Jun 2021

Asthma patients can benefit from type 2 diabetes medication

Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation.

21 May 2021

Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.

20 May 2021

Phase 3 trial: New biologic therapy improves outcomes in adults, adolescents with severe asthma

Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference.